Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has reported positive results from Cohort 2 of its pivotal PROGRESS study showing that ATEBRIOZ (zilurgisertib) reduced abnormal bone formation and was associated with improved clinician-assessed joint mobility in children aged six to under 12 years with fibrodysplasia ossificans progressiva. Announced on October 26, 2026, the findings demonstrated a reduction in mean total heterotopic ossification lesion volume of 8.09 cubic centimetres after 24 weeks of treatment, compared with a 9.14 cubic centimetre increase among patients receiving placebo.
The findings extend the clinical evidence supporting the oral activin receptor-like kinase 2 inhibitor into a younger pediatric population following its United States Food and Drug Administration approval in September 2026 for adults and children aged 12 years and older. Mirum plans to submit a supplemental new drug application during the first half of 2027 seeking to expand the approved indication to children aged six to under 12.
The development is significant because fibrodysplasia ossificans progressiva, commonly known as FOP, is an ultra-rare genetic disorder characterised by progressive formation of bone in muscles, tendons, ligaments and other soft tissues. The resulting accumulation of abnormal bone can progressively restrict mobility and cause severe, irreversible disability.
However, the latest findings come from a controlled cohort involving only 25 children, and the disclosed statistical evidence remains limited to a relatively short treatment period. The results support further regulatory evaluation but do not establish that zilurgisertib prevents all new bone formation, reverses established disability or provides a cure for FOP.
What do the PROGRESS Cohort 2 results reveal about abnormal bone formation in younger children?
PROGRESS Cohort 2 was a randomised, double-blind, placebo-controlled investigation involving 25 children aged six to under 12 years with genetically defined fibrodysplasia ossificans progressiva. Twelve participants received zilurgisertib 75 milligrams orally once daily, while 13 received placebo during a 24-week controlled treatment period.
The mean age at enrolment was 8.3 years, and participants had received their initial FOP diagnosis an average of five years earlier. All 25 children completed the double-blind treatment period and subsequently entered an open-label extension, providing an opportunity for additional safety and efficacy observation.
At Week 24, the mean change in total heterotopic ossification lesion volume was minus 8.09 cubic centimetres in the zilurgisertib group, compared with an increase of 9.14 cubic centimetres in the placebo group.
Mirum reported an estimated treatment difference of minus 14.0 cubic centimetres favouring zilurgisertib, with a nominal p-value of 0.003. The estimate was calculated using the Hodges-Lehmann method, while the p-value was derived from a Wilcoxon rank-sum test.
The distinction between the estimated treatment difference and the arithmetic difference between the two group means is important. Subtracting the reported means produces a numerical difference of 17.23 cubic centimetres, but that is not the same statistical quantity as the company’s reported Hodges-Lehmann estimate. The 14.0 cubic centimetre result should therefore be described specifically as the estimated treatment difference.
The reported mean changes were based on 12 zilurgisertib-treated patients and 13 placebo-treated patients, corresponding to the complete randomised cohort.
The magnitude of the separation suggests that treatment affected the process through which abnormal bone burden accumulates in FOP. However, the study’s small size creates uncertainty around the precision of the effect estimate and the degree to which it can be generalised across children with different disease characteristics.
The nominal p-value supports evidence of a treatment-associated difference, but the term should not be confused with a comprehensive confirmatory statistical analysis of every reported clinical outcome.
Longer follow-up will be important for determining whether the reduction in measured lesion burden persists and whether changes in heterotopic ossification translate into sustained functional benefit.
Why does the absence of new lesions require careful interpretation despite positive treatment results?
Mirum reported that none of the 12 children receiving zilurgisertib developed a new discrete heterotopic ossification lesion during the controlled treatment period.
In the placebo group, one of 13 patients developed a new lesion, representing approximately 7.7% of that group.
The absence of newly identified lesions among treated patients is an encouraging observation, but the difference between zero and one event in a 25-patient study is too small to establish that the medicine prevents new lesion development.
The principal treatment effect was measured through changes in total heterotopic ossification lesion volume. This measurement includes changes in the burden of abnormal bone associated with existing lesions, as well as the contribution from newly developing lesions.
Consequently, the main efficacy result should not be interpreted simply as a count of newly formed lesions. The treatment effect arose from volumetric assessment rather than a large difference in the number of patients developing new discrete lesions.
The reported reduction in measured lesion volume also does not establish that zilurgisertib can remove mature, established heterotopic bone or restore normal tissue architecture. Such conclusions would require separate clinical and imaging evidence.
This distinction matters because FOP involves progressive accumulation of abnormal bone, often accompanied by irreversible structural changes. A medicine capable of reducing further bone formation could provide meaningful benefit without reversing damage that has already occurred.
The longer-term clinical objective is therefore to preserve mobility and reduce progressive disability by limiting additional heterotopic ossification.
How does ATEBRIOZ target the underlying ALK2 signalling abnormality in fibrodysplasia ossificans progressiva?
Fibrodysplasia ossificans progressiva is associated with pathogenic variants in the ACVR1 gene, which encodes the activin receptor-like kinase 2 protein.
ALK2 participates in bone morphogenetic protein signalling, a biological pathway involved in skeletal development and tissue regulation. In FOP, abnormal receptor activation contributes to inappropriate bone formation within tissues that would not normally undergo ossification.
This creates a direct biological rationale for therapies that inhibit ALK2 signalling. Rather than merely addressing inflammation or symptoms associated with a flare-up, such medicines seek to interfere with a pathway involved in the disease’s abnormal bone-forming process.
Zilurgisertib is an orally administered small-molecule ALK2 inhibitor developed to reduce this inappropriate signalling activity.
The medicine does not correct the underlying genetic mutation. Instead, it is intended to interfere pharmacologically with the biological consequences of that mutation.
The Phase 2 findings support this therapeutic rationale because patients receiving zilurgisertib experienced a reduction in measured heterotopic ossification burden relative to placebo.
Nevertheless, inhibition of a disease-associated signalling pathway does not necessarily prevent every manifestation of FOP. The condition involves complex biological and structural consequences that may continue to affect patients even when new bone formation is reduced.
Determining whether sustained ALK2 inhibition can preserve functional independence over many years will require evidence beyond the initial 24-week assessment.
The longer-term value of treatment may also depend on when therapy begins relative to the accumulation of irreversible skeletal and soft-tissue damage.
What do the joint mobility findings reveal about potential functional improvement in children?
The PROGRESS Cohort 2 results included assessments using the Cumulative Analogue Joint Involvement Scale, commonly known as CAJIS.
This clinician-assessed scale measures functional limitations associated with FOP across relevant joint regions. Scores range from zero, indicating no impairment, to 30, indicating maximum impairment.
At Week 24, children receiving zilurgisertib experienced a mean improvement of 0.80 points, compared with an improvement of 0.09 points among patients receiving placebo.
The mobility analysis involved 10 evaluable children in the zilurgisertib group and 11 in the placebo group, making the population slightly smaller than the full randomised cohort.
The observed difference is directionally consistent with the reduction in abnormal bone lesion volume. It suggests that the biological effect measured through imaging may be accompanied by changes in physical function.
However, Mirum did not report a confirmatory p-value or prespecified statistical conclusion establishing that the between-group CAJIS difference was statistically significant.
The clinical meaning of a 0.80-point improvement also requires interpretation within the disease’s natural history. FOP generally involves progressive mobility restriction, and the company referenced evidence indicating that untreated patients experience average CAJIS deterioration of approximately 0.5 points annually.
That historical comparison provides useful context but is not a substitute for the concurrent placebo-controlled analysis.
The ability of a treatment to preserve joint mobility may be particularly relevant during childhood, when irreversible limitations could affect education, personal care, physical independence and later adult functioning.
However, the 24-week results do not demonstrate that the observed improvements will persist or translate into long-term improvements in daily activities.
Further follow-up will be needed to establish whether changes in CAJIS scores are sustained and whether treatment affects broader patient-reported functional outcomes.
What does the pediatric safety profile establish about long-term ALK2 inhibition during childhood?
Safety is a central consideration in FOP treatment because the disease often requires intervention during childhood and may necessitate prolonged treatment.
A medicine designed to influence bone-related signalling must be evaluated carefully in growing children, even when its mechanism is intended to suppress abnormal rather than normal skeletal development.
Mirum reported that zilurgisertib was generally well tolerated in PROGRESS Cohort 2 and that no new safety signals were identified during the 24-week controlled treatment period.
Most adverse events were mild or moderate, while serious adverse events and Grade 3 or higher events were described as infrequent and occurred less commonly among zilurgisertib-treated patients than among those receiving placebo.
No patient discontinued treatment during the double-blind period.
Importantly, the company reported that none of the zilurgisertib-treated children experienced growth plate closure during the disclosed observation period.
This finding is relevant because normal skeletal development remains an important safety consideration when treating children with disorders involving abnormal bone formation.
However, the absence of observed growth plate closure among 12 treated children over 24 weeks does not establish that the medicine has no potential effect on skeletal growth during prolonged use.
The company’s detailed safety disclosure identified arthralgia, cough, fever and vomiting in three zilurgisertib-treated children each. Alopecia, nosebleeds, falls, iron deficiency and nasopharyngitis were reported in two treated children each.
These events provide preliminary information about tolerability but do not independently establish treatment causation for every reported occurrence.
The existing United States prescribing information for ATEBRIOZ also includes important safety restrictions. The medicine is contraindicated during pregnancy because of embryo-fetal toxicity identified through nonclinical evidence, and its label describes potential interactions with selected medicines.
Those requirements remain relevant to the currently approved population and will form part of broader regulatory assessment as development expands.
Additional pediatric exposure will be necessary to characterise uncommon adverse events, skeletal development and longer-term tolerability.
How do the younger children’s results compare with the evidence supporting ATEBRIOZ’s September 2026 approval?
The FDA approved ATEBRIOZ on September 25, 2026, to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with FOP.
The approved starting dose for that population is 100 milligrams orally once daily, a distinction from the 75-milligram daily dose evaluated in the younger children enrolled in Cohort 2.
The original approval was supported by PROGRESS Cohort 1, which included 63 participants aged 12 years and older.
During the 24-week randomised treatment period, patients receiving zilurgisertib experienced an average decrease of 3.2 cubic centimetres in total new heterotopic ossification volume, while the placebo group recorded an average increase of 24.6 cubic centimetres.
The study subsequently continued through an open-label extension, with Mirum reporting that treatment effects were maintained through Week 48.
These findings established the clinical evidence underpinning the approved older-patient indication.
The results from Cohort 2 are consistent with the biological direction of the earlier study but should not be treated as directly comparable efficacy estimates.
The studies involve different ages, dosing regimens and baseline disease characteristics. The absolute changes in lesion volume may also be influenced by differences in initial lesion burden and disease activity.
A stronger conclusion is that two separately evaluated age populations have demonstrated favourable changes in imaging-based heterotopic ossification measurements following ALK2 inhibition.
The younger cohort now provides the evidence Mirum intends to use in pursuing an expansion of the existing regulatory label.
Until that expansion is approved, ATEBRIOZ remains authorised in the United States only for patients aged 12 years and older.
Why could ATEBRIOZ face a different competitive environment in younger pediatric FOP patients?
The United States treatment landscape for FOP has expanded considerably, with three medicines authorised by September 2026.
Ipsen’s SOHONOS (palovarotene) became the first FDA-approved treatment for FOP in August 2023. Its indication includes adults and girls aged eight years and older, as well as boys aged 10 years and older.
The medicine is a retinoid used to reduce new heterotopic ossification, but its prescribing information carries a boxed warning addressing embryo-fetal toxicity and premature epiphyseal closure in growing pediatric patients.
Regeneron Pharmaceuticals’ PASATRU (garetosmab-grts) received FDA approval in August 2026 to reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with FOP.
PASATRU is administered intravenously and targets activin A, providing a different therapeutic approach from direct ALK2 inhibition.
ATEBRIOZ subsequently became the third FDA-approved FOP treatment, with its authorised population beginning at age 12.
A successful label expansion would therefore bring another treatment option to children aged six to under 12, although the degree of competition would vary by age and sex because SOHONOS already has certain pediatric indications.
For younger children who fall below the approved SOHONOS thresholds, an expanded ATEBRIOZ indication could potentially address an age group with particularly limited authorised pharmacological options.
However, separate trials cannot establish that zilurgisertib is more effective or safer than palovarotene or garetosmab.
The three medicines have different mechanisms, eligible populations, administration requirements and evidence packages. Cross-trial comparisons based on isolated reductions in heterotopic ossification would therefore be unreliable.
The commercial significance of a new pediatric indication will depend on the approved label, reimbursement access, clinician assessment and the specific unmet needs of children who meet the eligibility criteria.
What will the FDA need to assess before expanding ATEBRIOZ to children aged six to under 12?
Mirum intends to submit a supplemental new drug application during the first half of 2027 seeking an expanded indication for children aged six to under 12 years.
The planned submission would build on the original approval and incorporate the new controlled pediatric evidence.
The FDA will need to assess whether the observed change in heterotopic ossification volume provides sufficient support for efficacy in the younger population and whether the proposed dosage offers an acceptable benefit-risk profile.
The agency may also evaluate how the 75-milligram study dose relates to exposure, body size and the approved 100-milligram starting dose in older patients.
Pediatric pharmacokinetic information could help establish whether the selected regimen provides appropriate exposure while accounting for age-related differences.
Longer-term safety will be especially relevant because the study population includes children undergoing continued skeletal development.
The open-label extension may provide additional data on repeated treatment exposure, lesion progression and mobility outcomes, although it does not preserve the same controlled comparison as the initial randomised period.
The company has not announced that the supplemental application has already been submitted or accepted for review. The first-half 2027 timetable therefore remains a management target rather than a confirmed regulatory milestone.
Mirum also continues enrolment in PROGRESS Cohort 3, which is evaluating zilurgisertib in children aged two to under 12.
That programme could support further investigation of younger patients, but its results and development timeline remain separate from the planned Cohort 2 supplemental submission.
How does the Incyte licensing agreement affect Mirum Pharmaceuticals’ commercial strategy?
Mirum obtained worldwide development and commercialisation rights to zilurgisertib from Incyte Corporation through a licensing agreement signed in April 2026.
Under the agreement, Mirum paid $16 million upfront and agreed to additional potential regulatory milestones of up to $48 million and commercial milestones of up to $15 million, together with royalties in the mid-to-high single-digit percentage range.
The structure gives Mirum the principal development and commercial responsibilities while allowing Incyte to retain economic participation in the medicine’s future success.
The September FDA approval established the basis for United States commercialisation, while the planned pediatric label expansion creates an opportunity to increase the authorised treatment population.
However, FOP is an ultra-rare condition. Mirum estimates that approximately 300 people in the United States and 900 worldwide are affected, meaning that commercial outcomes depend on a small, highly specialised population rather than large prescription volumes.
The company has established Mirum Access Plus to support eligible patients and healthcare providers with insurance coverage, reimbursement assistance and other access-related services.
Such infrastructure is particularly relevant in rare diseases because diagnosis, specialist referral, coverage requirements and individual treatment eligibility can influence whether an approved medicine reaches patients.
A new pediatric indication could expand the number of eligible patients, but it would not automatically guarantee widespread treatment uptake or reimbursement.
Mirum’s broader commercial business provides funding capacity for these activities. In its second-quarter 2026 financial results, the company reported global net product sales of $176.2 million, including $128.7 million from LIVMARLI and $47.5 million from its bile acid medicines portfolio.
The company also reported approximately $561.3 million in unrestricted cash, cash equivalents and investments at June 30, 2026.
These figures provide context for its ability to support rare disease commercialisation and clinical development, although they predate the September ATEBRIOZ approval and do not represent revenue generated by the newly authorised FOP treatment.
What does Mirum Pharmaceuticals’ latest stock performance indicate about investor expectations?
Mirum Pharmaceuticals shares closed at $83.27 on October 26, 2026, advancing 3.58% from the previous closing price of $80.39.
The gain coincided with the announcement of positive pediatric PROGRESS results, although the movement cannot be attributed exclusively to that disclosure.
The stock remained below its 52-week high of approximately $130, indicating that the company continued to trade within a wide valuation range despite its expanding commercial portfolio and recent regulatory success.
The pediatric data represent a potential regulatory expansion catalyst rather than a completely new commercial launch opportunity.
ATEBRIOZ had already received its first United States approval in September, meaning that investors were evaluating a medicine with an established regulatory status in older patients and a developing evidence package for younger children.
The immediate financial impact of the October results is limited by the absence of an approved label expansion and the relatively small underlying patient population.
Future value will depend on the supplemental application, the eventual authorised age range, treatment adoption and the commercial economics associated with Mirum’s licence.
Investors will also need to consider the company’s broader rare disease portfolio rather than assigning its valuation to a single FOP development.
What could determine ATEBRIOZ’s long-term importance in pediatric FOP treatment?
The Cohort 2 results provide controlled clinical evidence that zilurgisertib can reduce measured heterotopic ossification lesion volume in children aged six to under 12 years.
The observed reduction of 8.09 cubic centimetres, contrasted with an increase of 9.14 cubic centimetres on placebo, supports the biological rationale for ALK2 inhibition in a younger pediatric population.
The results are reinforced by favourable clinician-assessed mobility findings and the absence of new discrete lesions among treated participants during the disclosed observation period.
Nevertheless, the study involved only 25 children, and the duration of controlled follow-up was 24 weeks. The extent to which these effects translate into preserved mobility, lower disability and sustained clinical benefit over several years remains uncertain.
Longer-term evaluation will also be necessary to understand treatment safety during skeletal growth and to determine how consistently the medicine can be administered across childhood.
The next major milestone is the planned supplemental FDA submission in the first half of 2027. Regulatory acceptance and subsequent assessment will determine whether the approved ATEBRIOZ indication can extend below age 12.
The broader development programme involving children as young as two years may provide further information about treatment during earlier stages of FOP, although that population has not yet established the evidence necessary for approval.
For Mirum, the October 2026 findings strengthen the clinical foundation for expanding an already approved rare disease medicine. The more consequential test will be whether sustained ALK2 inhibition can reduce progressive abnormal bone formation over childhood while preserving physical function and maintaining an acceptable long-term safety profile.
